文献速递糖尿病

Advanced Hybrid Closed-Loop系统改善血糖结局:随机交叉试验对比自动胰岛素输注与预测性低血糖暂停

Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2021-02-12

这项双中心随机开放标签交叉研究在60例7-80岁、未使用过自动胰岛素输注的1型糖尿病患者中比较了MiniMed AHCL与SAP+PLGM,每阶段4周。AHCL组目标范围内时间(TIR)为70.4% vs 57.9%,提高12.5%(P<0.001),过夜改善更显著(18.8%,P<0.001)。低血糖时间<3.9 mmol/L降至2.1%(P=0.034),算法设定点5.6 mmol/L时TIR优于6.7 mmol/L(72.0% vs 64.6%),且未增加低血糖。

要点

  • AHCL较SAP+PLGM显著提高TIR达12.5%,过夜改善更明显。
  • 青少年(14-21岁)TIR改善幅度最大(14.4%)。
  • 算法设定点5.6 mmol/L时TIR更优且不增加低血糖。

核心结论

  • AHCL系统带自动校正大剂量功能,较SAP+PLGM显著改善血糖控制。
  • AHCL中较低的算法传感器葡萄糖设定点可带来更高TIR,且不增加低血糖。

研究设计与样本

  • 双中心、随机、开放标签、两序列交叉研究,纳入7-80岁未使用过自动胰岛素输注的1型糖尿病患者。
  • 比较AHCL与SAP+PLGM,每阶段4周,前有2-4周导入期,阶段间洗脱2周。
  • 60例中59例完成研究,平均年龄23.3±14.4岁。

主要发现

  • AHCL组TIR(3.9-10 mmol/L)为70.4±8.1%,SAP+PLGM组为57.9±11.7%,差异12.5±8.5%(P<0.001)。
  • 过夜TIR改善幅度为18.8±12.9%(P<0.001)。
  • 儿童(7-13岁)、青少年(14-21岁)和成人(>22岁)均有改善,青少年改善最大(14.4±8.4%)。
  • AHCL组平均传感器葡萄糖从导入期9.3±0.9 mmol/L降至8.5±0.7 mmol/L(P<0.001),PLGM组恶化至9.5±1.1 mmol/L(P<0.001)。
  • 算法设定点5.6 mmol/L时TIR为72.0±7.9%,优于6.7 mmol/L时的64.6±6.9%,且无额外低血糖。

关键数值与推荐

  • TIR目标范围3.9-10 mmol/L(70-180 mg/dL)。
  • AHCL算法设定点5.6 mmol/L(100 mg/dL)时TIR 72.0±7.9%,优于6.7 mmol/L(120 mg/dL)的64.6±6.9%。
  • AHCL组低血糖时间<3.9 mmol/L为2.1±1.4%,≤3.0 mmol/L为0.5±0.5%。

临床怎么用

  • 对于1型糖尿病患者,AHCL可显著提高TIR并减少低血糖时间。
  • 考虑将AHCL算法设定点设为5.6 mmol/L以优化TIR且不增加低血糖风险。
  • 需注意输注管路故障等可能导致糖尿病酮症酸中毒的风险。

局限性

  • 研究为开放标签设计,非盲法。
  • 每阶段仅4周,长期效果未评估。
  • 参与者为自动胰岛素输注初治者,结果可能不适用于有经验用户。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the MiniMed Advanced Hybrid Closed-Loop (AHCL) system, which includes an algorithm with individualized basal target set points, automated correction bolus function, and improved Auto Mode stability. RESEARCH DESIGN AND METHODS: This dual-center, randomized, open-label, two-sequence crossover study in automated-insulin-delivery-naive participants with type 1 diabetes (aged 7-80 years) compared AHCL to sensor-augmented pump therapy with predictive low glucose management (SAP + PLGM). Each study phase was 4 weeks, preceded by a 2- to 4-week run-in and separated by a 2-week washout. RESULTS: The study was completed by 59 of 60 people (mean age 23.3 ± 14.4 years). Time in target range (TIR) 3.9-10 mmol/L (70-180 mg/dL) favored AHCL over SAP + PLGM (70.4 ± 8.1% vs. 57.9 ± 11.7%) by 12.5 ± 8.5% (P < 0.001), with greater improvement overnight (18.8 ± 12.9%, P < 0.001). All age-groups (children [7-13 years], adolescents [14-21 years], and adults [>22 years]) demonstrated improvement, with adolescents showing the largest improvement (14.4 ± 8.4%). Mean sensor glucose (SG) at run-in was 9.3 ± 0.9 mmol/L (167 ± 16.2 mg/dL) and improved with AHCL (8.5 ± 0.7 mmol/L [153 ± 12.6 mg/dL], P < 0.001), but deteriorated during PLGM (9.5 ± 1.1 mmol/L [17 ± 19.8 mg/dL], P < 0.001). TIR was optimal when the algorithm set point was 5.6 mmol/L (100 mg/dL) compared with 6.7 mmol/L (120 mg/dL), 72.0 ± 7.9% vs. 64.6 ± 6.9%, respectively, with no additional hypoglycemia. Auto Mode was active 96.4 ± 4.0% of the time. The percentage of hypoglycemia at baseline (<3.9 mmol/L [70 mg/dL] and ≤3.0 mmol/L [54 mg/dL]) was 3.1 ± 2.1% and 0.5 ± 0.6%, respectively. During AHCL, the percentage time at <3.9 mmol/L (70 mg/dL) improved to 2.1 ± 1.4% (P = 0.034) and was statistically but not clinically reduced for ≤3.0 mmol/L (54 mg/dL) (0.5 ± 0.5%; P = 0.025). There was one episode of mild diabetic ketoacidosis attributed to an infusion set failure in combination with an intercurrent illness, which occurred during the SAP + PLGM arm. CONCLUSIONS: AHCL with automated correction bolus demonstrated significant improvement in glucose control compared with SAP + PLGM. A lower algorithm SG set point during AHCL resulted in greater TIR, with no increase in hypoglycemia.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Collyns OJ, Meier RA, Betts ZL, et al. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes. Diabetes Care. 2021. PMID: 33579715. doi:10.2337/dc20-2250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。